
Drug Development| Precision Oncology| Tissue-Agnostic Precision Medicine #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.
New York, NY
Joined March 2015
- Tweets30.4K
- Following2.2K
- Followers41.6K
- Likes34.4K
Vivek Subbiah, MD retweeted
Every treatment available today started as a clinical trial. Let’s Win helps patients and families learn about emerging treatments and trials. letswinpc.org/treatments/fin… #WPCD

ALT Two people stand closely, gazing towards the horizon with thoughtful expressions. One is older, and the other appears younger. The sky is colorful, suggesting a sunrise or sunset. Text on the image promotes the importance of clinical trials and directs viewers to the Let's Win Pancreatic Cancer website for more information.
Vivek Subbiah, MD retweeted
2/ @VivekSubbiah on normalized membrane ratio of TROP2 as a predictor of outcomes with Dato-DXd in NSCLC:
xitter.gq/VivekSubbiah/status/21…
The TROP2/NMR/QCS/ paper is out @NatureMedicine 👉Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
👉Scoring TROP2 IHC by eye doesn’t predict who benefits from TROP2 ADCs. Computational pathology does.
✅TROP2 QCS-NMR in TROPION-Lung01, NMR+ vs NMR–
👉Dato-DXd PFS 7.2 vs 4.0 mo (HR 0.40)
👉Docetaxel 4.1 vs 4.4 mo (HR 0.94)
👉An emerging predictive biomarker for Dato-DXd. #LCSM @OncoAlert @oncodaily nature.com/articles/s41591-0…
Vivek Subbiah, MD retweeted
We are recruiting for an outstanding clinical/translational leader and physician to serve as Section Chief, Thoracic Medical Oncology - contact me if interested @Perlmutter_CC @nyulangone @nyugrossman apply.interfolio.com/164896
Vivek Subbiah, MD retweeted
📣 Today #FDA approved giredestrant in combination with everolimus for adults with ER+/HER-/ESR1 mutated #MetastaticBreastCancer after prior endocrine therapy in adjuvant or advanced setting.
More detailed info here: fda.gov/drugs/cancer-approva….
#OncTwitter #bcsm #MedTwitter
Vivek Subbiah, MD retweeted
Clonal evolution. Wheler was here too but she left before the photo. Proud of these mentees and wonderful opportunity to see them at TargetCancer Foundation meeting for rare cancers. 🧨🦄🦓🎯💡👏
Vivek Subbiah, MD retweeted
Vivek Subbiah Reflects on Five Years of Progress and the Next Frontier in Rare Cancer Precision Oncology at Target Cancer Foundation’s Meeting
@VivekSubbiah @targetcancer
oncodaily.com/blog/vivek-sub…
Vivek Subbiah, MD retweeted
Vivek Subbiah Named Director of Early-Phase Drug Development and Rare Cancer Programs at NYU Langone
@VivekSubbiah
oncodaily.com/career/vivek-s…
RT @montypal: Critical guidance from the @AmericanCancer around #prostatecancer screening. These key changes will impact a much broader pop…
This quoted post is unavailable.
🚨Which clinical specialties are shielded from AI, and which are exposed? New @NEJM_AI , the authors measure how much of each specialty's work requires in-person physical interaction and what that means for AI's reach into practice.
👉"Physical Limits to AI Substitution across Physician Specialties- Implications for the Physician Workforce" @NEJM @NEJM_AI @OncoAlert ai.nejm.org/doi/full/10.1056…
🚨⭐️Your Outlook email may not be working & your flight may be delayed ✈️ so you might have a few minutes to read our Perspective, just published hot off the press @Nature @Nature_NPJ
👉Open access, free for all to read - at least @X & internet are working :) #precisionmedicine #AI
👉"AI-based prediction of actionable genomic alterations from H&E-stained slides" 🔬
👉Tissue exhaustion & slow turnaround still keep patients from the right targeted therapy. Deep learning models can now predict actionable genomic alterations directly from routine H&E, and the prospective EAGLE (EGFR, NSCLC) and ANNAR (FGFR, urothelial) studies show this holds across diverse global cohorts.
👉Near-instant, non-destructive results let us triage patients for molecular testing or clinical trials at the time of diagnosis. Every lab in the world makes an H&E slide, and this puts molecular information within reach of all of them @OncoAlert @oncodaily
nature.com/articles/s41698-0…
Vivek Subbiah, MD retweeted
Definitely best meeting for rare cancers. Honored to chair meeting and to hear Subbiah amazing talk 🔥🔥🦄🦓
⭐️One of my favorite meetings of the year is today: Target Cancer Foundation's Rare Cancer Precision Oncology meeting. @targetcancer @Dr_R_Kurzrock
⭐️Looking forward to delivering my lecture “AGNOSTIC BY DESIGN: Five Years That Redrew the Map of Rare Cancer Precision Oncology, & the Next Frontier” 🧬🎯🚀@OncoAlert @oncodaily @OncBrothers @OpenMedInsights @OpenMedKate
#TCFTargetcancer2026
#RareCancer #PrecisionOncology
targetcancer.org/research/th…
⭐️One of my favorite meetings of the year is today: Target Cancer Foundation's Rare Cancer Precision Oncology meeting. @targetcancer @Dr_R_Kurzrock
⭐️Looking forward to delivering my lecture “AGNOSTIC BY DESIGN: Five Years That Redrew the Map of Rare Cancer Precision Oncology, & the Next Frontier” 🧬🎯🚀@OncoAlert @oncodaily @OncBrothers @OpenMedInsights @OpenMedKate
#TCFTargetcancer2026
#RareCancer #PrecisionOncology
targetcancer.org/research/th…
The TROP2/NMR/QCS/ paper is out @NatureMedicine 👉Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
👉Scoring TROP2 IHC by eye doesn’t predict who benefits from TROP2 ADCs. Computational pathology does.
✅TROP2 QCS-NMR in TROPION-Lung01, NMR+ vs NMR–
👉Dato-DXd PFS 7.2 vs 4.0 mo (HR 0.40)
👉Docetaxel 4.1 vs 4.4 mo (HR 0.94)
👉An emerging predictive biomarker for Dato-DXd. #LCSM @OncoAlert @oncodaily nature.com/articles/s41591-0…
Vivek Subbiah, MD retweeted
Great things happen in pairs!!
National Leader in Cancer Symptom Management, Ishwaria Subbiah, MD, Joins @Perlmutter_CC @nyulangone
Welcome to PCC and New York City @IshwariaMD - we are so excited to have you and your family here.
@JohnPLeonardMD
nyulangone.org/news/national…
Vivek Subbiah, MD retweeted
Now this is a fantastic reason to return to X! Thank you, @Aiims1742, for the warm welcome. Thrilled to join @Perlmutter_CC, and grateful to you, @JohnPLeonardMD, and the superb PCC and #SuppOnc teams!
Great things happen in pairs!!
National Leader in Cancer Symptom Management, Ishwaria Subbiah, MD, Joins @Perlmutter_CC @nyulangone
Welcome to PCC and New York City @IshwariaMD - we are so excited to have you and your family here.
@JohnPLeonardMD
nyulangone.org/news/national…
Vivek Subbiah, MD retweeted
🏥 @nyulangone Perlmutter Cancer Center has appointed @VivekSubbiah, MD, Director of Early-Phase Drug Development and Rare Cancer Programs.
🩺 He brings 15+ years of experience in #PrecisionOncology and clinical research.
Learn more ➡️ ascopost.com/news/november-2…
⭐️New city, new chapter, same mission 🗽
⭐️Thrilled to have joined @nyulangone @Perlmutter_CC to lead Early Phase Drug Development and the Rare Cancer Programs.
⭐️For patients with rare cancers, #PrecisionMedicine should open the door to treatment. Expanding access to early-phase trials is how we make that real.
⭐️My work has always been tumor-agnostic. That continues here, now geography agnostic & zip code agnostic too.
⭐️Such a delight to be in NY with family. Grateful to @Aiims1742, @JohnPLeonardMD & @nyuniversity @nyulangone visionary leadership for bringing me here!
⭐️Thank you to all my friends & colleagues for the wishes & the outpouring of support🙏
@OncoAlert @oncodaily @ASCO @ASCOPost tinyurl.com/238ks5m5
🏥 @nyulangone Perlmutter Cancer Center has appointed @VivekSubbiah, MD, Director of Early-Phase Drug Development and Rare Cancer Programs.
🩺 He brings 15+ years of experience in #PrecisionOncology and clinical research.
Learn more ➡️ ascopost.com/news/november-2…
Vivek Subbiah, MD retweeted
Beyond excited to recruit @VivekSubbiah to @nyulangone @Perlmutter_CC as the new director of our Early Phase Drug Development Program and the Rare Cancer Program.
Congratulate Vivek when you see him at #ESMO26. Welcome to NYC!
@JohnPLeonardMD
nyulangone.org/news/perlmutt…



























